Testing the molecular profile of prostate tumours identifies which patients with advanced prostate cancer are more likely to benefit from a chemotherapy treatment called docetaxel and live longer, ...
According to the World Cancer Research Fund, more than 100,000 men are newly diagnosed with prostate cancer annually in Japan, and a portion of those patients will be diagnosed with or later progress ...
Testing the molecular profile of tumors identifies which patients with advanced prostate cancer are more likely to benefit from chemotherapy and live longer, sparing patients less likely to benefit ...
Improving Oncotype DX turnaround time for timeliness of adjuvant therapy: A single-system, multi-site quality improvement study in early-stage HR-positive breast cancer. This is an ASCO Meeting ...
BOCA RATON, Fla., Jan. 22, 2026 /PRNewswire/ -- Doctors Studio by Forum Health, LLC today announced pilot findings indicating that intraprostatic ozone therapy was associated with measurable molecular ...
Natera's integration into OncoEMR enhances workflow efficiency, simplifying the ordering process for precision medicine tests in oncology practices. The integration supports timely treatment decisions ...
For decades, the story of prostate cancer screening has been dominated by three letters: P-S-A. The Prostate-Specific Antigen blood test is the first line of defense for millions of men. Yet, for all ...
Impact of a diagnostic bronchoscopy service with embedded reflex molecular testing within an oncology centre in patients with lung cancer: The Bronchiomics study. This is an ASCO Meeting Abstract from ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results